
Clover Biopharmaceuticals, Ltd. (HKEX: 02197) reports positive Phase Ⅰ trial results for SCB-219M, a thrombopoietin receptor agonist addressing chemotherapy-induced thrombocytopenia (CIT). All 9 enrolled cancer patients receiving SCB-219M with chemotherapy maintained platelet counts >75 x 109/L after one week, lasting through at least three weeks. The durable efficacy and favorable pharmacokinetic profile may support convenient dosing intervals ≥2 weeks, a significant improvement over current treatment options in China and globally. Phase Ⅰb trial for repeated dosing in CIT and CTIT patients is set to commence in 2024.
Like
Save
Share